Reversible airflow obstruction in lymphangioleiomyomatosis

Angelo M. Taveira-DaSilva, Wendy K. Steagall, Antoinette Rabel, Olanda Hathaway, Sergio Harari, Roberto Cassandro, Mario Stylianou, Joel Moss

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: We previously reported that approximately one-fourth of patients with lymphangio-leiomyomatosis (LAM) may respond to therapy with bronchodilators. However, the validity of those observations has been questioned. The aims of the present study were to determine the prevalence of reversible airflow obstruction in patients with LAM and to identify associated clinical and physiologic parameters. Methods: First, the clinical and physiologic characteristics of 235 patients were analyzed to determine the frequency of the response to albuterol during a total of 2,307 visits. Second, we prospectively evaluated the response to albuterol (2.5 mg) and ipratropium (500 μg) in 130 patients, and correlated their responses with their clinical and physiologic characteristics. Results: In the retrospective study, 51% of the patients responded at least once to bronchodilators; of these, 12% responded ≥ 50% of the time. A higher frequency of positive bronchodilator responses was associated with greater rates of decline in FEV1 and diffusing capacity of the lung for carbon monoxide (DLCO). In the prospective study, 39 patients (30%) responded to bronchodilators, including 12 to ipratropium, 9 to albuterol, and 18 to both. The prevalence of asthma and smoking in the 39 responders was not different from that seen in the 91 nonresponders. Patients who responded to ipratropium, albuterol, or both had significantly (p <0.02) lower FEV1 and DLCO, and a greater rate of FEV1 decline (p = 0.044) and DLCO decline (p = 0.039) than patients who did not respond to these bronchodilators. After adjusting for FEV1/FVC ratio, DLCO decline also was greater in responders than in nonresponders (p = 0.009). Conclusions: Patients with LAM may have partially reversible airflow obstruction. A positive response to bronchodilators is associated with an accelerated rate of decline in pulmonary function.

Original languageEnglish
Pages (from-to)1596-1603
Number of pages8
JournalChest
Volume136
Issue number6
DOIs
Publication statusPublished - Dec 1 2009

Fingerprint

Lymphangioleiomyomatosis
Bronchodilator Agents
Leiomyomatosis
Albuterol
Ipratropium
Lung Volume Measurements
Carbon Monoxide
Asthma
Retrospective Studies
Smoking
Prospective Studies

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Taveira-DaSilva, A. M., Steagall, W. K., Rabel, A., Hathaway, O., Harari, S., Cassandro, R., ... Moss, J. (2009). Reversible airflow obstruction in lymphangioleiomyomatosis. Chest, 136(6), 1596-1603. https://doi.org/10.1378/chest.09-0624

Reversible airflow obstruction in lymphangioleiomyomatosis. / Taveira-DaSilva, Angelo M.; Steagall, Wendy K.; Rabel, Antoinette; Hathaway, Olanda; Harari, Sergio; Cassandro, Roberto; Stylianou, Mario; Moss, Joel.

In: Chest, Vol. 136, No. 6, 01.12.2009, p. 1596-1603.

Research output: Contribution to journalArticle

Taveira-DaSilva, AM, Steagall, WK, Rabel, A, Hathaway, O, Harari, S, Cassandro, R, Stylianou, M & Moss, J 2009, 'Reversible airflow obstruction in lymphangioleiomyomatosis', Chest, vol. 136, no. 6, pp. 1596-1603. https://doi.org/10.1378/chest.09-0624
Taveira-DaSilva AM, Steagall WK, Rabel A, Hathaway O, Harari S, Cassandro R et al. Reversible airflow obstruction in lymphangioleiomyomatosis. Chest. 2009 Dec 1;136(6):1596-1603. https://doi.org/10.1378/chest.09-0624
Taveira-DaSilva, Angelo M. ; Steagall, Wendy K. ; Rabel, Antoinette ; Hathaway, Olanda ; Harari, Sergio ; Cassandro, Roberto ; Stylianou, Mario ; Moss, Joel. / Reversible airflow obstruction in lymphangioleiomyomatosis. In: Chest. 2009 ; Vol. 136, No. 6. pp. 1596-1603.
@article{ea91737b316248aea5c414ce2fb38de7,
title = "Reversible airflow obstruction in lymphangioleiomyomatosis",
abstract = "Background: We previously reported that approximately one-fourth of patients with lymphangio-leiomyomatosis (LAM) may respond to therapy with bronchodilators. However, the validity of those observations has been questioned. The aims of the present study were to determine the prevalence of reversible airflow obstruction in patients with LAM and to identify associated clinical and physiologic parameters. Methods: First, the clinical and physiologic characteristics of 235 patients were analyzed to determine the frequency of the response to albuterol during a total of 2,307 visits. Second, we prospectively evaluated the response to albuterol (2.5 mg) and ipratropium (500 μg) in 130 patients, and correlated their responses with their clinical and physiologic characteristics. Results: In the retrospective study, 51{\%} of the patients responded at least once to bronchodilators; of these, 12{\%} responded ≥ 50{\%} of the time. A higher frequency of positive bronchodilator responses was associated with greater rates of decline in FEV1 and diffusing capacity of the lung for carbon monoxide (DLCO). In the prospective study, 39 patients (30{\%}) responded to bronchodilators, including 12 to ipratropium, 9 to albuterol, and 18 to both. The prevalence of asthma and smoking in the 39 responders was not different from that seen in the 91 nonresponders. Patients who responded to ipratropium, albuterol, or both had significantly (p <0.02) lower FEV1 and DLCO, and a greater rate of FEV1 decline (p = 0.044) and DLCO decline (p = 0.039) than patients who did not respond to these bronchodilators. After adjusting for FEV1/FVC ratio, DLCO decline also was greater in responders than in nonresponders (p = 0.009). Conclusions: Patients with LAM may have partially reversible airflow obstruction. A positive response to bronchodilators is associated with an accelerated rate of decline in pulmonary function.",
author = "Taveira-DaSilva, {Angelo M.} and Steagall, {Wendy K.} and Antoinette Rabel and Olanda Hathaway and Sergio Harari and Roberto Cassandro and Mario Stylianou and Joel Moss",
year = "2009",
month = "12",
day = "1",
doi = "10.1378/chest.09-0624",
language = "English",
volume = "136",
pages = "1596--1603",
journal = "Chest",
issn = "0012-3692",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Reversible airflow obstruction in lymphangioleiomyomatosis

AU - Taveira-DaSilva, Angelo M.

AU - Steagall, Wendy K.

AU - Rabel, Antoinette

AU - Hathaway, Olanda

AU - Harari, Sergio

AU - Cassandro, Roberto

AU - Stylianou, Mario

AU - Moss, Joel

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Background: We previously reported that approximately one-fourth of patients with lymphangio-leiomyomatosis (LAM) may respond to therapy with bronchodilators. However, the validity of those observations has been questioned. The aims of the present study were to determine the prevalence of reversible airflow obstruction in patients with LAM and to identify associated clinical and physiologic parameters. Methods: First, the clinical and physiologic characteristics of 235 patients were analyzed to determine the frequency of the response to albuterol during a total of 2,307 visits. Second, we prospectively evaluated the response to albuterol (2.5 mg) and ipratropium (500 μg) in 130 patients, and correlated their responses with their clinical and physiologic characteristics. Results: In the retrospective study, 51% of the patients responded at least once to bronchodilators; of these, 12% responded ≥ 50% of the time. A higher frequency of positive bronchodilator responses was associated with greater rates of decline in FEV1 and diffusing capacity of the lung for carbon monoxide (DLCO). In the prospective study, 39 patients (30%) responded to bronchodilators, including 12 to ipratropium, 9 to albuterol, and 18 to both. The prevalence of asthma and smoking in the 39 responders was not different from that seen in the 91 nonresponders. Patients who responded to ipratropium, albuterol, or both had significantly (p <0.02) lower FEV1 and DLCO, and a greater rate of FEV1 decline (p = 0.044) and DLCO decline (p = 0.039) than patients who did not respond to these bronchodilators. After adjusting for FEV1/FVC ratio, DLCO decline also was greater in responders than in nonresponders (p = 0.009). Conclusions: Patients with LAM may have partially reversible airflow obstruction. A positive response to bronchodilators is associated with an accelerated rate of decline in pulmonary function.

AB - Background: We previously reported that approximately one-fourth of patients with lymphangio-leiomyomatosis (LAM) may respond to therapy with bronchodilators. However, the validity of those observations has been questioned. The aims of the present study were to determine the prevalence of reversible airflow obstruction in patients with LAM and to identify associated clinical and physiologic parameters. Methods: First, the clinical and physiologic characteristics of 235 patients were analyzed to determine the frequency of the response to albuterol during a total of 2,307 visits. Second, we prospectively evaluated the response to albuterol (2.5 mg) and ipratropium (500 μg) in 130 patients, and correlated their responses with their clinical and physiologic characteristics. Results: In the retrospective study, 51% of the patients responded at least once to bronchodilators; of these, 12% responded ≥ 50% of the time. A higher frequency of positive bronchodilator responses was associated with greater rates of decline in FEV1 and diffusing capacity of the lung for carbon monoxide (DLCO). In the prospective study, 39 patients (30%) responded to bronchodilators, including 12 to ipratropium, 9 to albuterol, and 18 to both. The prevalence of asthma and smoking in the 39 responders was not different from that seen in the 91 nonresponders. Patients who responded to ipratropium, albuterol, or both had significantly (p <0.02) lower FEV1 and DLCO, and a greater rate of FEV1 decline (p = 0.044) and DLCO decline (p = 0.039) than patients who did not respond to these bronchodilators. After adjusting for FEV1/FVC ratio, DLCO decline also was greater in responders than in nonresponders (p = 0.009). Conclusions: Patients with LAM may have partially reversible airflow obstruction. A positive response to bronchodilators is associated with an accelerated rate of decline in pulmonary function.

UR - http://www.scopus.com/inward/record.url?scp=73149108212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73149108212&partnerID=8YFLogxK

U2 - 10.1378/chest.09-0624

DO - 10.1378/chest.09-0624

M3 - Article

C2 - 19447921

AN - SCOPUS:73149108212

VL - 136

SP - 1596

EP - 1603

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6

ER -